Cover Image
市場調查報告書

肥厚性心肌症:開發中產品分析

Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361623
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
肥厚性心肌症:開發中產品分析 Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 60 Pages
簡介

本報告提供肥厚性心肌症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

肥厚性心肌症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肥厚性心肌症:企業開發中的治療藥

肥厚性心肌症:大學/機關研究中的治療藥

肥厚性心肌症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肥厚性心肌症:企業開發中的產品

肥厚性心肌症:大學/機關研究中的產品

肥厚性心肌症的治療藥開發企業

  • Gilead Sciences, Inc.
  • Heart Metabolics Limited
  • miRagen Therapeutics, Inc.
  • MyoKardia, Inc.

肥厚性心肌症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肥厚性心肌症:最近的開發平台趨勢

肥厚性心肌症:暫停中的計劃

肥厚性心肌症:開發中止的產品

肥厚性心肌症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8743IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Hypertrophic Cardiomyopathy.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Hypertrophic Cardiomyopathy Overview 7
  • Therapeutics Development 8
  • Pipeline Products for Hypertrophic Cardiomyopathy - Overview 8
  • Pipeline Products for Hypertrophic Cardiomyopathy - Comparative Analysis 9
  • Hypertrophic Cardiomyopathy - Therapeutics under Development by Companies 10
  • Hypertrophic Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 11
  • Hypertrophic Cardiomyopathy - Pipeline Products Glance 12
  • Late Stage Products 12
  • Clinical Stage Products 13
  • Early Stage Products 14
  • Hypertrophic Cardiomyopathy - Products under Development by Companies 15
  • Hypertrophic Cardiomyopathy - Products under Investigation by Universities/Institutes 16
  • Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development 17
  • Gilead Sciences Inc 17
  • Heart Metabolics Ltd 18
  • Lead Discovery Center GmbH 19
  • miRagen Therapeutics Inc 20
  • MyoKardia Inc 21
  • Hypertrophic Cardiomyopathy - Therapeutics Assessment 22
  • Assessment by Monotherapy Products 22
  • Assessment by Target 23
  • Assessment by Mechanism of Action 25
  • Assessment by Route of Administration 27
  • Assessment by Molecule Type 28
  • Drug Profiles 30
  • eleclazine - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • HCM-2 - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • LUS-1 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • MGN-9103 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • MYK-461 - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • perhexiline maleate - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • ranolazine ER - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • Small Molecule for Cardiac Hypertrophy - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 45
  • Product Description 45
  • Mechanism Of Action 45
  • R&D Progress 45
  • Hypertrophic Cardiomyopathy - Dormant Projects 46
  • Hypertrophic Cardiomyopathy - Discontinued Products 47
  • Hypertrophic Cardiomyopathy - Product Development Milestones 48
  • Featured News & Press Releases 48
  • Nov 11, 2016: MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients 48
  • Nov 02, 2016: MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy 48
  • Sep 21, 2016: MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day 49
  • Aug 31, 2016: Heart Metabolics Announces Initiation of Phase 2b Study of Perhexiline for Hypertrophic Cardiomyopathy 51
  • Jul 14, 2016: SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy 52
  • Jul 11, 2016: MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients 53
  • May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy 54
  • Mar 15, 2016: Heart Metabolics Announces Multiple Senior Appointments to Management Team 55
  • Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy 55
  • Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy 56
  • Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 57
  • Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 58
  • Appendix 59
  • Methodology 59
  • Coverage 59
  • Secondary Research 59
  • Primary Research 59
  • Expert Panel Validation 59
  • Contact Us 59
  • Disclaimer 60

List of Tables

  • Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2016 8
  • Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H2 2016 9
  • Number of Products under Development by Companies, H2 2016 10
  • Number of Products under Investigation by Universities/Institutes, H2 2016 11
  • Comparative Analysis by Late Stage Development, H2 2016 12
  • Comparative Analysis by Clinical Stage Development, H2 2016 13
  • Comparative Analysis by Early Stage Development, H2 2016 14
  • Products under Development by Companies, H2 2016 15
  • Products under Investigation by Universities/Institutes, H2 2016 16
  • Hypertrophic Cardiomyopathy - Pipeline by Gilead Sciences Inc, H2 2016 17
  • Hypertrophic Cardiomyopathy - Pipeline by Heart Metabolics Ltd, H2 2016 18
  • Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, H2 2016 19
  • Hypertrophic Cardiomyopathy - Pipeline by miRagen Therapeutics Inc, H2 2016 20
  • Hypertrophic Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2016 21
  • Assessment by Monotherapy Products, H2 2016 22
  • Number of Products by Stage and Target, H2 2016 24
  • Number of Products by Stage and Mechanism of Action, H2 2016 26
  • Number of Products by Stage and Route of Administration, H2 2016 27
  • Number of Products by Stage and Molecule Type, H2 2016 29
  • Hypertrophic Cardiomyopathy - Dormant Projects, H2 2016 46
  • Hypertrophic Cardiomyopathy - Discontinued Products, H2 2016 47

List of Figures

  • Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2016 8
  • Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H2 2016 9
  • Number of Products under Development by Companies, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 14
  • Assessment by Monotherapy Products, H2 2016 22
  • Number of Products by Targets, H2 2016 23
  • Number of Products by Stage and Targets, H2 2016 23
  • Number of Products by Mechanism of Actions, H2 2016 25
  • Number of Products by Stage and Mechanism of Actions, H2 2016 25
  • Number of Products by Stage and Routes of Administration, H2 2016 27
  • Number of Products by Molecule Types, H2 2016 28
  • Number of Products by Stage and Molecule Types, H2 2016 28
Back to Top